Communiqués AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:23 17/04/2025			Varia. 5j.	Varia. 1 janv.
10 124,00 ^GBX	-1,27%		+4,73%	-3,29%

17/04	Une filiale d'AstraZeneca poursuivie pour monopole présumé sur le médicament à succès Soliris	RE
17/04	Une filiale d'AstraZeneca fait l'objet d'un recours collectif aux États-Unis pour utilisation abusive du brevet Soliris	MT

Communiqués

Cinclus Pharma publishes its Annual Report for 2024	17/04	AQ
Bitter pill: UK scrambles to shield pharma	17/04	AQ
AstraZeneca : Results of Annual General Meeting held on 11 April 2025	12/04	PU
NICE recommends new combination breast cancer drug	11/04	AQ
AstraZeneca : Result of AGM	11/04	PU
AstraZeneca : Special Business Approved at AGM	11/04	PU
CPI launches first-of-a-kind digitalisation framework	09/04	AQ
Daiichi Sankyo - DATROWAY Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	09/04	AQ
AstraZeneca : showcases innovation in infectious disease protection at ESCMID Global 2025	08/04	PU
Daiichi Sankyo - ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy	07/04	AQ
AstraZeneca : Imfinzi approved in EU for AEGEAN	04/04	PU
AstraZeneca : Enhertu approved in EU in post-ET breast cancer	04/04	PU
Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca	02/04	AQ
AstraZeneca - Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma	01/04	AQ
AstraZeneca - Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer	01/04	AQ
AstraZeneca : AZD0780 Investor brochure (AZD0780 ACC 2025 Investor Brochure)	01/04	PU
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial	31/03	BU
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer	31/03	BU
AstraZeneca : Calquence recommended for EU approval in 1L MCL	31/03	PU
AstraZeneca : Imfinzi approved in the US for bladder cancer	31/03	PU
AstraZeneca - Alexion data presented at the 2025 AAN Annual Meeting highlight advancements in improving care for rare neurological diseases	28/03	AQ
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings	26/03	BU
AstraZeneca : New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings	25/03	PU
China courts American, European multinationals amid growing global trade tensions	24/03	AQ
AstraZeneca to invest $2.5 billion in new global strategic R&D centre, biotech agreements and manufacturing in Beijing	24/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

ASTRAZENECA : Les ventes du quatrième trimestre et les prévisions pour 2025 ont dépassé les attentes

Le 06 février 2025 à 14:36

Pascal Soriot, PDG d'AstraZeneca : Une amélioration de deux mois de survie a été observée pour un nouveau traitement du cancer du poumon

Le 10 septembre 2024 à 13:48